Ultimovacs
Menu
Close
✕
About
About Ultimovacs
Team
Board of directors
Technology
Technology overview
Immunotherapy
Clinical Studies
Phase II trials
Phase I trials
Partnering
Expanded access
Investors
Shares
Financial reports
Presentations and publications
Investor relations contacts
Analyst coverage
Governance
ESG
News
Contact
Ultimovacs
–
Investors
–
ESG
ESG
ESG documents
ESG Guidelines
ESG Report 2022